Close menu




December 21st, 2022 | 08:48 CET

BASF, BioNTech, Cardiol Therapeutics: Stocks for 2023?

  • Biotechnology
  • chemicals
  • Investments
Photo credits: BASF SE

Is there a 400% upside potential in 2023? At the end of a challenging 2022 stock market year, we are looking ahead to the new year. Which share is worth buying, and which is better left alone? In the case of BASF, the high dividend yield is one of the attractions. The latest company news shows that the chemical group is also involved in the mega market of electromobility. But the dependence on gas supplies is causing uncertainty, and an analyst has renewed a sell recommendation for BASF shares. BioNTech, on the other hand, is looking good, even if the chart picture has recently clouded over. The development pipeline is full, capacities - especially in Asia - are being expanded, and analysts are also more courageous again. Investors also need a little courage and, above all, patience with Cardiol Therapeutics. They could soon be rewarded. The cash position of the biotech pearl is almost equal to the market capitalization, the main product is already in the Phase 2 pilot study, and analysts see massive upside potential.

time to read: 5 minutes | Author: Fabian Lorenz
ISIN: BASF SE NA O.N. | DE000BASF111 , BIONTECH SE SPON. ADRS 1 | US09075V1026 , CARDIOL THERAPEUTICS | CA14161Y2006

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Cardiol Therapeutics: Analysts optimistic about the start of Phase 2

    Analysts at Leede Jones Gable Inc. have renewed their buy recommendation on Cardiol Therapeutics' stock. They said the Canadian biotech company has now started the Phase 2 pilot study following strong preclinical data for its lead product CardiolRx. Analysts expect new data during the coming year. Cardiol Therapeutics is thus on track, the analysts said. Their price target for the share, which is also traded on the NASDAQ and in Germany (e.g. Tradegaze), is CAD 4.50. Currently, the stock is trading at CAD 0.80, which is on par with its cash position.

    Cardiol Therapeutics specializes in cardiovascular diseases. Its lead product, CardiolRx, is designed to treat pericarditis. Preclinical data already showed a convincing anti-inflammatory effect. The Phase 2 study with 25 patients is being conducted at two renowned cardiology centers in the USA. "The initiation of this meaningful study at the Cleveland Clinic and Mayo Clinic is an important milestone in our efforts to improve treatment options for patients with recurrent pericarditis," said Cardiol CEO David Elsley. "Recurrent pericarditis is an inflammatory heart disease with symptoms such as stabbing chest pain, shortness of breath and fatigue that limit physical activity and quality of life for those affected. Data from patients enrolled in the study at our collaborating research centers will provide further information to support the use of CardiolRx as a novel therapy for this debilitating and often undertreated condition. We are excited about the start of the study and share the enthusiasm with which the study investigators are exploring the clinical potential of CardiolRx in pericarditis."

    BioNTech: Technical setback, but full throttle operationally

    BioNTech can enter 2023 with a lot of confidence. Thanks to billions in revenue from the COVID-19 vaccine, the Company has a substantial product pipeline and can move full throttle ahead. At the same time, the mRNA specialists from Mainz are preparing for mass production of their vaccines. A research institute is being built in Melbourne, and in Singapore BioNTech has taken over the one production facility from Novartis. The Company is also expanding in Taiwan. There, trials of BNT113 are to be conducted in patients with head and neck tumors. In this effort, BioNTech is collaborating with the YongLin Healthcare Foundation and Retain Biotech. "Taiwan is one of the most renowned biomedical hubs in the Asia-Pacific region due to its state-of-the-art healthcare system, medical research capacity, and collaborative approach to working with leading companies and institutions around the world. Our Asia-Pacific strategy is built on strong partnerships and a shared vision," said Sean Marett, Chief Business and Chief Commercial Officer of BioNTech. "We look forward to working with Retain in our efforts to facilitate the clinical development of novel immunotherapies in oncology. Our goal is to accelerate the development of innovative therapies to combat cancers that are prevalent in the region."

    From a chart perspective, the picture has darkened somewhat in recent days. The breakout from the sideways trend of 2022 was not successful. In a weak overall market, the Mainz share fell by around 10% in a few days. But if analysts have their way, 2023 should be worthwhile for shareholders. After analysts had been conspicuously quiet for a few weeks, there were two positive comments at once. Bank of America, for example, upgraded BioNTech's stock from "Neutral" to "Buy." The analysts' price target for the stock is USD 239. Bryan Garnier & Co experts also believe that BioNTech's share has upside potential. Their price target is USD 250.

    BASF shares at EUR 38 or EUR 72?

    2022 was not a good year for the BASF share. Meanwhile, the share price had almost halved. That is because the DAX-listed company is more dependent on gas than any other company in Germany. It would therefore be massively affected by a gas freeze. However, the operating performance has been stable, and the dividend yield is now around 7%. Nevertheless, investors should not be blinded by this. UBS has issued a "Sell" recommendation for BASF shares. The price target is EUR 38. The stock is currently trading at EUR 45. BASF - like the European chemical industry - will probably come through the winter months relatively well. The reasons for this are the high gas reserves, government subsidy packages and, in some cases, long-term energy contracts. For 2023, however, the analysts are skeptical about BASF. They rather bet on companies from the industrial gases segment in the sector. Bernstein Research is more optimistic. The US analysts trust BASF's share price to reach EUR 72 and recommend it with an "outperform" rating. In particular, BASF's agricultural business is full of opportunities. Demand from agricultural companies in the corn and soybean sectors looks fundamentally sound.

    But BASF is also active in future markets. Take electromobility, for example; BASF is conducting research on innovative cathode materials that will further advance electromobility. Innovations from BASF for high-performance lithium-ion batteries are expected to help double the real-world range of a mid-size car from 300 to 600 km by 2025 and significantly reduce the charging time of electric cars. There is news along the way: for example, BASF's majority-owned Ludwigshafen-based TODA Battery Materials (BTBM) has delivered the first batch of nickel-cobalt-manganese (NCM) cathode materials to Prime Planet Energy & Solutions (PPES). The customer is a joint venture between Toyota and Panasonic. "This is a great joint success between BASF and PPES teams in Japan and an important step for further cooperation between the two companies," said Michael Baier, SVP of BASF Battery Materials. "It fits well with BASF's strategy to co-develop cathode materials with leading battery manufacturers in their respective home markets and expand the business for more growth globally." In addition to cathode materials for lithium-ion batteries, BASF is working on components for next-generation batteries, such as solid-state batteries.


    The stock market year 2023 promises to be exciting. This also applies to individual stocks such as BASF, BioNTech and Cardiol Therapeutics. The latter is currently trading at cash while making clear progress with its main product. At BioNTech, a brisk newsflow from cancer research is expected in the coming year. If there is a surprising easing of tensions in the war between Russia and Ukraine, BASF is quite the bargain.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Juliane Zielonka on February 22nd, 2024 | 07:00 CET

    Royal Helium, Fresenius, BASF: Chemical and Healthcare industry - Where is the next investment opportunity?

    • Helium
    • Healthcare
    • chemicals

    Europe is in the midst of an industrial upheaval due to the Green Deal, which presents both challenges and opportunities for investors. While companies like BASF are arguing for deregulation and increased subsidies to support the green transition, healthcare company Fresenius is undergoing a period of radical change and realignment. The medical technology market is booming. The global MedTech market size amounted to USD 574,002.45 million in 2022 and is expected to increase to USD 814,159.2 million by 2028, with an annual growth rate of 6.0%. Critical raw materials such as helium are in particularly high demand. Royal Helium is one of the producers of this valuable gas and impresses with a well thought-out and sustainable business model. Where does the next investment opportunity lie?

    Read

    Commented by Fabian Lorenz on February 21st, 2024 | 07:00 CET

    Top news: BYD, Bayer and Globex Mining

    • Mining
    • Gold
    • Commodities
    • Electromobility
    • chemicals

    Bayer shocked investors yesterday with the announcement of its dividend cut, which shouldn't have been much of a surprise. The Company is burdened with high debt, endless legal fines, and an empty pharmaceutical pipeline. In an initial reaction, analysts have lowered the share price target. BYD, on the other hand, is doing well operationally. Only the share price is not picking up. Will a share buyback turn the share price around? For those who want to profit from the commodity boom with reduced risk, then Globex Mining's stock is attractive. The news flow is strong, and those who act quickly can still register and follow the live presentation of the mining incubator at the 10th International Investment Forum, IIF, today.

    Read

    Commented by André Will-Laudien on February 20th, 2024 | 07:30 CET

    Takeover fever in the biotech sector! Will MorphoSys now be followed by Defence Therapeutics, Evotec and Bayer?

    • Biotechnology
    • Pharma
    • Innovations

    It has happened: Novartis is bidding for MorphoSys. Once again, a long-lasting and persistent rumour mill eventually confirms itself. Those who remained loyal to MorphoSys despite heavy selling last fall have now made a profit of over 300%. If we turn the analytical magnifying glass on the sector, we can see that the speculative biotech stock market segment has started to move again since the challenging year 2023. Hopes of falling interest rates in the near future, along with several other M&A hopes, have led to steady inflows into listed bio-ETFs, resulting in fund managers having recently adjusted their weightings upwards. We analyze which stocks are currently making the loudest noise.

    Read